JP6826040B2 - 安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物 - Google Patents

安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物 Download PDF

Info

Publication number
JP6826040B2
JP6826040B2 JP2017543288A JP2017543288A JP6826040B2 JP 6826040 B2 JP6826040 B2 JP 6826040B2 JP 2017543288 A JP2017543288 A JP 2017543288A JP 2017543288 A JP2017543288 A JP 2017543288A JP 6826040 B2 JP6826040 B2 JP 6826040B2
Authority
JP
Japan
Prior art keywords
composition
tpa
minutes
thrombolytic
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017543288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533961A (ja
JP2017533961A5 (enExample
Inventor
グレウィッチ，ビクター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thrombolytic Science LLC
Original Assignee
Thrombolytic Science LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombolytic Science LLC filed Critical Thrombolytic Science LLC
Publication of JP2017533961A publication Critical patent/JP2017533961A/ja
Publication of JP2017533961A5 publication Critical patent/JP2017533961A5/ja
Application granted granted Critical
Publication of JP6826040B2 publication Critical patent/JP6826040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2017543288A 2014-11-03 2015-11-03 安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物 Active JP6826040B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074374P 2014-11-03 2014-11-03
US62/074,374 2014-11-03
PCT/US2015/058878 WO2016073514A2 (en) 2014-11-03 2015-11-03 Methods and compositions for safe and effective thrombolysis

Publications (3)

Publication Number Publication Date
JP2017533961A JP2017533961A (ja) 2017-11-16
JP2017533961A5 JP2017533961A5 (enExample) 2018-12-06
JP6826040B2 true JP6826040B2 (ja) 2021-02-03

Family

ID=55910021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543288A Active JP6826040B2 (ja) 2014-11-03 2015-11-03 安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物

Country Status (10)

Country Link
US (2) US11213574B2 (enExample)
EP (2) EP3708226A1 (enExample)
JP (1) JP6826040B2 (enExample)
CN (1) CN107073292B (enExample)
CA (1) CA2966332C (enExample)
DK (1) DK3215221T3 (enExample)
EA (1) EA035358B1 (enExample)
ES (1) ES2788697T3 (enExample)
MX (1) MX383561B (enExample)
WO (1) WO2016073514A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073292B (zh) 2014-11-03 2021-07-02 溶栓科学有限责任公司 用于安全和有效的溶栓的方法和组合物
US11154596B2 (en) 2017-06-16 2021-10-26 Thrombolytic Science, Llc Methods for thrombolysis
CN107516010B (zh) * 2017-08-19 2021-02-09 上海矩点医疗科技有限公司 溶栓剂量模型的构建方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381346A (en) 1979-11-13 1983-04-26 Huasin Syed S Isolation of plasminogen activators useful as therapeutic and diagnostic agents
GB8623823D0 (en) 1986-10-03 1986-11-05 Sandoz Ltd Therapeutic lysis of fibrin blood clots
GB2197195B (en) 1986-10-03 1991-01-23 Sandoz Ltd Improvments in or relating to organic compounds
US5108901A (en) 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
GB8823833D0 (en) 1988-10-11 1988-11-16 Erba Carlo Spa Production of human prourokinase
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
JP3559559B2 (ja) * 1992-06-03 2004-09-02 ジェネンテク，インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
EP0682700A4 (en) 1993-02-05 1997-05-28 Vascular Lab USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE.
US5472692A (en) 1993-07-02 1995-12-05 New England Deaconess Hospital Corporation Pro-urokinase mutants
US5510330A (en) 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US5810767A (en) 1994-05-11 1998-09-22 Localmed, Inc. Method and apparatus for pressurized intraluminal drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5569197A (en) 1994-12-21 1996-10-29 Schneider (Usa) Inc Drug delivery guidewire
WO1996021224A1 (en) 1994-12-29 1996-07-11 Sony Corporation Disk cartridge
US6759042B2 (en) 1999-06-04 2004-07-06 Thrombotech Ltd Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US6699230B2 (en) 2000-05-10 2004-03-02 Minnesota Medical Physics, Llc Apparatus and method for out-of-hospital thrombolytic therapy
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
CN1142278C (zh) 2001-04-04 2004-03-17 刘建宁 一类能被尿激酶或自身激活的尿激酶原变体及其编码基因、制备方法和用途
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US7070958B2 (en) 2003-04-18 2006-07-04 Thrombolytic Science, Inc. Methods of making pro-urokinase mutants
CA2426115A1 (en) 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
JP2006241109A (ja) 2005-03-04 2006-09-14 Paion Deutschland Gmbh ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質
US8071532B2 (en) * 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
US20070298024A1 (en) * 2006-06-22 2007-12-27 Thrombolytic Science, Inc. C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis
US20090010916A1 (en) * 2006-06-22 2009-01-08 Victor Gurewich C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
CN101015686B (zh) * 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
CN101549150A (zh) * 2008-03-31 2009-10-07 刘建宁 尿激酶原及尿激酶原变体在急性心肌梗塞易化经皮冠状动脉介入中的应用
CN107073292B (zh) 2014-11-03 2021-07-02 溶栓科学有限责任公司 用于安全和有效的溶栓的方法和组合物

Also Published As

Publication number Publication date
EA035358B1 (ru) 2020-06-01
ES2788697T3 (es) 2020-10-22
US12590301B2 (en) 2026-03-31
CN107073292B (zh) 2021-07-02
MX383561B (es) 2025-03-14
CN107073292A (zh) 2017-08-18
JP2017533961A (ja) 2017-11-16
DK3215221T3 (da) 2020-05-11
US20220184189A1 (en) 2022-06-16
HK1243666A1 (en) 2018-07-20
CA2966332A1 (en) 2016-05-12
WO2016073514A3 (en) 2016-08-11
CA2966332C (en) 2024-04-16
EP3708226A1 (en) 2020-09-16
WO2016073514A2 (en) 2016-05-12
EA201790969A1 (ru) 2017-11-30
MX2017005793A (es) 2017-10-23
BR112017008749A2 (pt) 2017-12-19
EP3215221A4 (en) 2018-08-08
EP3215221A2 (en) 2017-09-13
US11213574B2 (en) 2022-01-04
EP3215221B1 (en) 2020-02-26
US20180311322A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
Dzik Reversal of drug‐induced anticoagulation: old solutions and new problems
Lyden et al. Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers
US12590301B2 (en) Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
Hennan et al. Effect of tiplaxtinin (PAI‐039), an orally bioavailable PAI‐1 antagonist, in a rat model of thrombosis
CZ81997A3 (en) Pharmaceutical preparation for treating disorders connected with blood clotting, process of its preparation and use
JP2023052764A (ja) 急性虚血性脳卒中の処置のための方法及び医薬組成物
Wang et al. Intravenous release of NO from lipidic microbubbles accelerates deep vein thrombosis resolution in a rat model
Gurewich et al. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator
CN113597313A (zh) 用于治疗和预防微血栓形成的纤溶酶原
CN113350355B (zh) GSK923295和伊斯平斯作为重组tPA激动剂在制备溶栓药物中的应用
US20110229454A1 (en) Use of Prourokinase and Variants Thereof in Facilitated Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction
Le Sache et al. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit
Rajput et al. Neuroprotection and vasculoprotection using genetically targeted protease-ligands
HK1243666B (en) Methods and compositions for safe and effective thrombolysis
JP2001520200A (ja) ウロキナーゼタイプのプラスミノーゲン活性化因子の内在化および分解を促進するための組成物および方法
US11154596B2 (en) Methods for thrombolysis
JP5509085B2 (ja) 血栓溶解についての新規な患者亜群
WO2007149141A2 (en) C1-inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thromolysis
BR112017008749B1 (pt) Composição para o uso no tratamento de um sujeito com sintomas de um acidente vascular cerebral ou infarto do miocárdio agudo, kits e usos da mesma
Datta et al. A case of limb-threatening hematoma in a patient taking citalopram and apixaban concurrently
Prentice et al. Plasminogen activation and the coagulation process
Mounika Role of Tranexamic Acid in Oral Surgery.
WO2003099324A1 (en) Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
Morton Latest advances in thrombolytic therapy
JP2011500617A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210114

R150 Certificate of patent or registration of utility model

Ref document number: 6826040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250